PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of currneuroLink to Publisher's site
 
Curr Neuropharmacol. Sep 2012; 10(3): 263–271.
Published online Sep 2012. doi:  10.2174/157015912803217323
PMCID: PMC3468880
The Developing Utility of Zebrafish Models for Cognitive Enhancers Research
Adam Michael Stewart1* and Allan V Kalueff2,3
1Brain-Body Center, Department of Psychiatry, University of Illinois at Chicago, 1601 W. Taylor Ave., Chicago, IL 60612, USA
2Department of Pharmacology and Neuroscience Program, Zebrafish Neuroscience Research Consortium, Tulane University Medical School, SL-83, 1430 Tulane Avenue, New Orleans, LA 70112, USA
3ZENEREI Institute, 309 Palmer Court, Slidell, LA 70458, USA
* Address correspondence to this author at the Brain-Body Center, Department of Psychiatry, University of Illinois at Chicago, 1601 W. Taylor Ave., Chicago, IL 60612, USA; Tel: 412-447-1259; E-mail: astewart/at/psych.uic.edu
Received May 13, 2012; Revised June 22, 2012; Accepted July 9, 2012.
Whereas cognitive impairment is a common symptom in multiple brain disorders, predictive and high-throughput animal models of cognition and behavior are becoming increasingly important in the field of translational neuroscience research. In particular, reliable models of the cognitive deficits characteristic of numerous neurobehavioral disorders such as Alzheimer’s disease and schizophrenia have become a significant focus of investigation. While rodents have traditionally been used to study cognitive phenotypes, zebrafish (Danio rerio) are gaining popularity as an excellent model to complement current translational neuroscience research. Here we discuss recent advances in pharmacological and genetic approaches using zebrafish models to study cognitive impairments and to discover novel cognitive enhancers and neuroprotective mechanisms.
Keywords: Cognition, cognitive enhancers, drug screening, neurobehavioral disorders, neuroprotective agents, zebrafish.
Cognitive impairment is a common symptom in multiple brain disorders, including Alzheimer’s disease (AD), Huntingdon’s disease, autism and schizophrenia [1-4]. With the growing global elderly population, and cognitive decline observed with age, there is an urgent need for effective treatments of age- and neurodegenerative-related cognitive deficits [5]. With the limited spectrum of therapies currently available, and the general lack of model systems that fully recapitulate pathogenesis, predictive and high-throughput animal models become particularly important in the field of cognitive research [6, 7].
While rodents have traditionally been used to study cognitive phenotypes [8-12], expanding the range of experimental domains and animal models is recognized as an important strategy of translational neuroscience research [13]. Although modeling neurobehavioral and cognitive disorders has primarily employed rodents in tests of learning, memory and attention [8, 14-16], non-mammalian vertebrates and invertebrates such as Drosophila melanogaster, Caenorhabditis elegans and several fish species, have emerged as “complementary models” for such research [8].
Due to their complex nervous system and elaborate behavioral repertoire, zebrafish (Danio rerio) are gaining popularity as an excellent intermediate model between in vitro and in-vivo mammalian models for drug screening [7]. Drug discovery has traditionally utilized systemic, target-based screening in purified proteins or cells as primary screens, with in vivo models as tertiary screens after more mechanistic cell assays. Although in vitro screens have been successful in identifying molecules affecting known mechanisms, there is still the need to identify modulators of complex in vivo phenotypes in the whole organism for less well understood pathways – especially those occurring in a physiological and/or pathophysiological context. From this point of view, zebrafish offer a significantly higher throughput in vivo screening for phenotypic endpoints compared to other animal models [7, 17].
Furthermore, zebrafish possess robust cognitive abilities, including learning and memory. For example, both associative and non-associative learning has been extensively tested in zebrafish, including cue-based and spatial learning as well as long-term and short-term memory [18-22]. Habituation, extensively investigated in animal models as an evolutionarily conserved adaptive behavior relevant to cognition [22-25], is also being increasingly assessed in zebrafish, as researchers continue to decipher the complexity of fish behaviors [21, 22, 26]. Notably, the habituation response in zebrafish can be modulated through various pharmacological manipulations, and is either attenuated or abolished depending on the receptor class targeted by the drug [26]. Memory has also been well studied in zebrafish, with the animals demonstrating the ability to recall a spatial alternation task for up to 10 days after testing [27]. Importantly, zebrafish cognition is also subject to normal aging processes, as conditioned responses to spatial, visual and temporal cues (associated with changes in cognitive responses to emotionally positive and negative experiences) show reduced generalization of adaptive associations, increased stereotypic and reduced exploratory behavior, and altered temporal entrainment over the course of the zebrafish lifespan [28, 29].
Since the genome and genetic pathways controlling signal transduction and development are highly conserved between zebrafish and humans [30], various molecular tools available render zebrafish particularly useful for determining the mechanisms of action of various classes of psychoactive drugs [31]. Zebrafish models of brain disorders underlying cognitive deficits can also be useful to screen potentially neuroprotective or nootropic compounds for drug development, revealing the mechanisms crucial for new therapeutic treatments [31]. Collectively, this suggests that zebrafish represent a useful model in cognitive neuroscience research [7, 8, 17, 31].
With its small size and transparent larvae, the zebrafish also provides an ideal system to apply novel tools for imaging targeted subsets of neurons and manipulating their activity [32]. Their utility in the recently developed field of optogenetics is increasingly allowing researchers to link neural activity with behavior and detect biological events at the cellular level [33-37]. These novel approaches foster the ability to predict how changes in circuit function may lead to altered cognition and behavior relevant to neurobehavioral disorders [38]. Here we discuss recent advances in pharmacological, genetic and optogenetic approaches using zebrafish models to study cognitive impairments and search for novel cognitive enhancers.
Numerous assays have been developed to study zebrafish cognition (Table 11). For example, the three-chambered tank assesses spatial and nonspatial escape and avoidance discrimination learning, in which the choice behavior and response latency of zebrafish can be measured in the context of spatial and nonspatial discrimination [39]. The roles of motivation and fear/anxiety-like behavior in cognitive processes like learning and memory have been particularly well characterized in zebrafish, with both positive and negative reinforcement demonstrated in the conditioned place preference (CPP) and aversion paradigms [28, 40, 41]. In the CPP test, zebrafish (like rodents) show a preference for an environment that has previously been associated with a substance (e.g., drug or food reward), thus indicating the positive-reinforcing qualities of that substance [40]. The CPP has recently gained recognition for its use studying the cognitive enhancing effects of nootropic drugs in zebrafish. For example, we have shown that chronic exposure to the nootropic drug piracetam significantly improves fish performance in the cued learning test [41], similar to the nootropic effects seen in humans [42, 43] and rodents [44, 45]. Briefly, we used a cued-learning plus-maze test, which consisted of a transparent, four-armed, plus-shaped maze with each individual arm and a central square. One arm was randomly designated as the target arm using a custom-made gel bait as a reinforcement stimulus. To evoke cued learning, a red plastic cue card was placed adjacent to the reward arm, which was randomly changed to prevent bias. In order to evaluate the potential nootropic effects of piracetam, behavioral quantification was performed for the following endpoints: latency to the target arm, the number of target arms, incorrect arm and total arm entries, as well as the duration in the target or incorrect arms (see [41, 46] for further background and protocol details).
Table 1.
Table 1.
Selected Behavioral Assays Used for Assessing Cognitive Function in Zebrafish
The sensitivity of cognitive and several behavioral phenotypes to drugs such as piracetam supports the utility of zebrafish in developing novel screens for compounds with potential cognitive enhancing or neuroprotective properties [41]. For example, modafinil has been shown to improve attention for well-rested individuals, while maintaining wakefulness, memory and executive functions [47, 48]. However, while modafinil has similar effects on the sleep-wake cycle in larval zebrafish as it does in mammals (e.g., increasing wakefulness by lengthening wake-bouts) [49], the potential cognitive enhancing effects of this drug have not yet been investigated in aquatic models, and merit further scrutiny. Other potential drugs of interest include phenotropil, meclophenoxate, semax, oxiracetam, nefiracetam and aniracetam, which also exert nootropic effects in rodents [50-52], and may be active in other model species as well.
Similar to rodents [53-55], evidence of higher cognitive functions in zebrafish suggests that key loci (and, most likely, cognitive maps) can also be created by fish [56-58]. In rodents, homebases serve as “safe” home sites to which animals repeatedly return after exploring the environment, as well as strategic “reference points” to orient and organize their exploration [53]. Recently, the ability to establish such homebases has been reported in zebrafish, suggesting that this behavior can be sensitive to various agents modulating cognitive functions [56, 57]. In line with this prediction, our pilot studies testing the psychotropic hallucinogenic drug ibogaine [59] showed a striking increase in zebrafish homebase behavior following acute 20-min ibogaine exposure (which is, perhaps, not surprising given the ability of ibogaine to modulate cognitions in humans and rodents [60-62]). We have also recently shown that zebrafish, like rodents, scale their locomotor activity depending on the size of the tank and exhibit an inherent behavioral organization in a new environment [63]. Collectively, these findings provide viable assays for measuring altered cognition in fish during their exploration of novel environments.
The utility of zebrafish to study age-related impairments in cognitive function has also recently been recognized. Compared to other models such as C. elegans, Drosophila and mice, the relatively long life span (3–5 years) of zebrafish offer a distinct advantage for aging research, providing a model of very gradual rather than rapid decline in specific physiological functions and systems, similar to that observed in humans [28, 64]. In line with this, several behavioral models have been established to assess zebrafish cognition within the aging process, such as the degree of place preference or avoidance, latency to initiating exploration, and choice between the arms within the T-maze [28, 65]. Notably, the age-related changes associated with zebrafish behavior and cognition appears to be subject to genetic and environmental factors. For example, increases in actelylcholine levels delay the onset of age-related changes in cognition, whereas the genotoxic stress of gamma-irradiation accelerates cognitive decline [28].
Of considerable importance is the extension of zebrafish behavioral assays to modeling the cognitive and behavior phenotypes arising from specific neurobehavioral disorders. Schizophrenia, for example, is characterized by a multitude of positive and negative symptoms, including social withdrawal as well as cognitive deficits [66]. Mice have traditionally been used to study these behavioral abnormalities, including deficits in working memory, sensory motor gating and hyperlocomotion [67-69]. Pre-pulse inhibition (PPI) is also often employed in mouse to establish the relevance of a model to schizophrenia, examine gene function and test potential therapeutics [69]. As an evolutionarily advantageous response (providing protection from dangers in the natural habitat), the startle response in adult and larval zebrafish can be modulated by weak prepulses in a manner similar to mammalian PPI. For example, administration of the dopamine agonist apomorphine to larval zebrafish has recently been shown to suppress PPI of the startle response [70]. Importantly, the ability to study the modulation of PPI in the zebrafish startle response may provide the opportunity to define the neural circuitry underlying a basic form of behavioral regulation and offer insights into neurobehavioral disorders such as schizophrenia [7, 70]. Importantly, zebrafish may be well suited for other assays commonly used to examine cognitive processes relevant to schizophrenia. In particular, whereas schizophrenic patients show deficits in 2-D object recognition tasks, the novel object recognition (NOR) test (similar to the visual paired-comparison task in humans) [71, 72] has been widely utilized in rodent models of schizophrenia [73-75]. Given that zebrafish display overt behaviors related to novel object inspection, including altered approach latency, freezing and shoaling [76], extension of the NOR test to zebrafish models of schizophrenia may be a promising avenue of investigation.
The investigation of novel drug targets for treating cognitive impairments associated with neurological and psychiatric disorders is an important focus of neurobehavioral research. Many promising therapies are progressing through preclinical and clinical development, and offer the potential of improved treatment options for cognitive impairments in AD and schizophrenia. The use of both adult and larval zebrafish in large scale, high-throughput screens for various psychotropic drugs has been extensively validated [77-79]. Given the sensitivity of zebrafish behavior and cognition to various pharmacological manipulations [78, 80], they represent a promising novel organism to study the effects of psychotropic compounds, such as those that may attenuate cognitive impairment in models of neurological disorders.
The cognitive deficits observed in aging and neurodegenerative disorders (e.g., AD) have been linked to decreased cholinergic transmission [81-84]. While acetylcholinesterase (AChE) inhibitors are currently the first line treatment for AD [85, 86], they have been less promising therapeutically, producing only modest improvements in cognitive function with undesirable side effects [87-89]. Thus, agents which increase the release of acetylcholine by direct activation of presynaptic nicotinic acetylcholine receptors (nAChRs) have been suggested as a potential alternative [90]. For example, nicotinic agonists (including nicotine) improve memory function in multiple cognitive assays in rodents and monkeys, while impairments have been frequently reported following treatment with nicotinic antagonists [91-94]. The pro-cognitive effects of nicotine have been established in several animal models [91, 92, 94], and the genetic linkage between nAChRs and several cognitive deficiencies has also been established clinically [95, 96]. Overall, the importance of nAChR subtypes in modulating cognitive processes has been extensively validated, suggesting that activation of nAChR by selective nAChR ligands may be a viable approach to enhance cognitive performance. With the growing support for neuronal nAChRs as valid pharmacological targets, zebrafish have been recently used as a model system to study the role of specific nAChR subtypes [97, 98]. Notably, the zebrafish genome contains the complete complement of human neural nAChR subunit genes. For 8 of the 12 human genes, exactly one zebrafish ortholog exists, while for the 4 remaining human genes, two zebrafish homologs have been identified [99, 100]. Thus, while zebrafish have been used to assess the effects of nicotine on cognitive function [39, 101, 102], their role in studying nAChRs as putative drug targets is becoming particularly promising.
While nAChRs have been implicated extensively in human and animal studies of attention, learning and memory, the α4ß2 and α7 nicotinic receptor subunits (comprising the majority of the nicotinic receptor subtypes within the brain) are heavily involved in cognitive functioning [103]. Notably, both nicotinic α7 and α4β2 receptors have recently been implicated in the nicotinic anxiolysis in zebrafish, and are significantly attenuated by either α7 or α4β2 antagonists [104].
Evidence suggests that nAChRs may contribute to cognitive function by acting in local circuits of the hippocampus and cerebral cortex. For example, in the rodent hippocampus, α7-containing nAChRs are located postsynaptically on inter-neurons (where they mediate fast cholinergic excitatory synaptic transmission) and presynaptically (where their activation increases intra-terminal Ca2+ levels and facilitates glutamate release) [105-107]. The hippocampus receives afferent projections, and contains a wide distribution or α7 nAChR receptors, thereby rendering it an ideal circuit to study the effects of α7 in sensory gating. In particular, deficits in PPI in sensory gating have been shown in schizophrenic patients, and serve as a primary means of assessing higher-order processing known to be involved in cognitive functioning. [108-110]. Moreover, PPI is also capable of being modulated in rodents as a function of nAChR activation [111-113]. In line with this, modulation of PPI in the zebrafish startle response may also be possible, similar to the response observed following dopamine agonist administration [70].
Similar to the effects demonstrated in humans [114-116] and rodents [117-119], antipsychotic drugs suppress PPI disruptions evoked in the zebrafish startle test [70]. However, whereas antipsychotic drugs are widely used for the treatment of psychotic symptoms in patients with schizophrenia, typical (first-generation) antipsychotics often lead to severe motor side effects due to the blockade of dopamine D2 receptors [120]. Alternatively, atypical (second-generation) antipsychotics are increasingly used in the treatment of schizophrenia [121]. Atypical antipsychotics, although less potent in blocking central D2 receptors, have affinity for a wide range of other receptors including dopaminergic D1 and D4, serotonergic 5-HT2A, 5-HT6 and 5-HT7, adrenergic α1, histaminergic H1, and muscarinergic M1 [122, 123]. In line with this, acute exposure to the NMDA antagonist dizocilpine (MK-801) induces psychoses-like deficits in cognition and social interaction, which can be reversed by acute administration of atypical, but not typical, antipsychotics [124]. Zebrafish demonstrate high sensitivity to MK-801-induced psychotic-like effects, which are also attenuated in this aquatic model by antipsychotics [125-127].
Finally, while the main focus of this paper is on the use of zebrafish for testing cognitive enhancers, this sensitive animal model can also be used to study the opposite aspect – screening drugs that impair memory. Indeed, several studies have shown the sensitivity of zebrafish to ketamine, MK-801, scopolamine, and ethanol all known to disrupt memory [128-131]. Therefore, the possibility of using zebrafish-based screens to test memory-inhibiting drugs also seems promising.
The ease of genetic manipulations and the robust behaviors of zebrafish make them particularly amenable to functional and genetic dissection [132]. Early development of the zebrafish nervous system has been well characterized, presenting an effective model for studying development and disease processes in the nervous system [133]. Notably, morpholino antisense oligonucleotides (MO), mRNA or transgenes all alter gene expression and can be observed in the transparent zebrafish embryo. MOs can be designed to block translation of a particular gene or to block the splicing of particular exons into transcripts. Over-expression studies can also be performed by injecting sense mRNA of a gene. Finally, transgenic zebrafish can also be developed by using efficient vectors (e.g., the “sleeping beauty” transposase system) to insert genes under the control of tissue-specific promoters [134].
Importantly, zebrafish are increasingly utilized to investigate the molecular mechanisms underlying several brain disorders. For example, AD pathogenesis occurs through several pathways, with AD brain characterized by amyloid beta (Aβ) peptide deposition leading to amyloid plaques and neurofibrillary tangles (NFT) as well as aberrant presenilins. Three genes clinically implicated in AD pathogenesis are APP, presenilin 1 (PS1) and presenilin 2 (PS2), as their mutations have been identified in cases of familial AD [135]. In line with this, mice lacking the orthologues Psen1 and Psen2 in their forebrain show multiple phenotypes resembling AD [136]. Similarly, orthologues of PS1 and PS2 have also been identified in zebrafish (psen1 and psen2), demonstrating a highly conserved alignment in primary structure with human proteins. Such conservation has allowed for in vivo analysis, using homozygous null psen1 mutants displaying decreased cell proliferation and neurogenesis [134]. Since presenilin proteins are ubiquitously expressed, transgenic expression of mutated psen1 genes in zebrafish lacking endogenous psen1 activity can further elucidate the effects on psen1 function of mutations causing AD [137].
Morpholino antisense methods have been applied in zebrafish to examine potential cognitive and neurological impairment that may arise from subtle abnormalities in brain development due to alterations in the functions of candidate susceptibility genes. In particular, susceptibility genes underlying the pathogenesis of schizophrenia, such as Disrupted-in-schizophrenia 1 (DISC1) and Neuregulin 1 (NRG1), are increasingly being examined within zebrafish to provide novel insights into their role in brain development [138]. Whereas mouse models with mutations in Disc1 have behavioral and pathological alterations characteristic of schizophrenia [139, 140], efforts to characterize the expression profiles of these key genes have revealed a similar development and functionality to their mammalian homologues [138]. Additionally, morpholino technology has recently been utilized in a zebrafish model of attention-deficit/hyperactivity disorder (ADHD) [141, 142]. For example, the disruption of Latrophilin 3 (LPHN3) gene function produces a hyperactive/impulsive motor phenotype which can be reversed by ADHD drugs such as methylphenidate and atomoxetine [142]. Overall, significant utility of morpholino technology lies in its ability to correlate gene activity and behavioral phenotypes with the development of the brain circuitry.
In parallel with pharmacological and genomic modeling of cognitive impairment, mounting evidence shows the feasibility of detecting and tracking these diseases via disease-specific morphological signatures [143]. For example, clinical imaging studies have linked AD to brain atrophy [144, 145] and Parkinson’s disease to decreased grey matter [146, 147]. In line with this, the application of bioimaging techniques to several animal models and the development of digital brain atlases are revealing the bidirectional relationships between functional connectivity and disease pathology such as neurodegeneration [143]. Such connectome-based analyses in conjunction with digital atlas technology further increases our understanding of how cognitive processes emerge from their morphological substrates, and how these processes are affected when this structural substrate is disrupted [148].
With the growing utilization of zebrafish in neuroscience research, a population-based atlas of the zebrafish brain has recently been established, serving as a digital reference for anatomical localization comprising delineations based upon multiple magnetic resonance sequences and histological stains [143]. This publically available atlas provides important information on the spatial relationships of neuronal structures, as well as quantitative information and an accurate stereotaxic coordinate system. The combination of voxel-based comparisons and parametric comparisons for individual regions may also allow the effects of genetic and/or environmental manipulation on the anatomical phenotype to be assessed [143]. Recently, digital atlas data has also been further integrated with the visualization of gene expression data to allow researchers to identify spatiotemporal and quantitative aspects of gene expression in different stages of zebrafish development [149].
The use of connectome-based analyses helps to comprehensively map the neural connections from the level of single neurons and synapses (microscale) to the level of anatomically distinct brain regions and inter-regional pathways (macroscale) [148, 150-152]. While currently focused on the human brain, connectome-based approaches may be further extended to animal models of neuropathology [152]. For example, the use of Brainbow imaging techniques has successfully revealed the connectivity between different neural populations in mice and Drosophila [153-155]. With rapid advances in the fields of optical microscopy and fluorescent dyes, further incentive to use an optically accessible model such as the zebrafish is supported. As zebrafish have fewer neurons than mice, more extensive networks of connectivity between different brain regions may be determined, also reflecting other highly dynamic processes, such as axon growth and pruning, which may be used as potential biomarkers of cognitive functions [156].
With the advent of new genetically encoded optical tools, researchers have recently begun to directly manipulate neuronal firing, probe neuronal-circuit function and control behavior on milliseconds timescales. The emergence of optogenetics has enabled monitoring and control of neuronal activity with minimal perturbation and unprecedented spatiotemporal resolution [157-161]. Briefly, light-gated channels and pumps allow the activation and silencing of neurons, while fluorescent proteins further allow for the sensing of calcium or membrane potential. Importantly, such optogenetic tools provide significant opportunities for analyzing neural circuits, especially those involved in cognitive and behavioral disorders [158, 161, 162]. For example, circuit-level perturbations in the brain's electrical activity may underlie cognitive deficits in schizophrenia and autism – disorders hypothesized to arise from hyperexcitation within neural microcircuitry. However, direct investigation of cell- and circuit-level effects of changes in cellular excitation has been precluded, as cell-specific pharmacological agents are lacking, and homeostatic processes can occur downstream of synaptic and intrinsic excitability alterations. Emerging optogenetics techniques have recently begun to bridge this gap, having been applied to study altered cellular excitation as well as quantify the effects on information transmission network activity in freely moving animals [162].
Zebrafish offer an ideal system to apply optical techniques for imaging the nervous system, as well as genetically encoded tools for targeting subsets of neurons and manipulating their activity [32]. Notably, its small size allows all neurons from a defined circuit to be monitored at once under a laser scanning microscope. For example, photoconvertible proteins can define and image circuits as well as link zebrafish behaviors with neuronal development, such as in developing spinal circuitry controlling tail movements in larvae [163]. Optical reporters of neuronal activity have also been useful for mapping brain regions with specific topographic arrangements in zebrafish, such as mapping the olfactory bulb in explants from adult zebrafish during their responses to odors [164]. Furthermore, numerous studies have applied optogenetic techniques to link neural activity with behavior in zebrafish. Specifically, optogenetic tools have been used in zebrafish to detect biological events at the cellular level, such as voltage spikes, increased intracellular Ca2 +, and the fusion of neurotransmitter-bearing vesicles [33-35, 37].
Since the first optogenetic studies in zebrafish several years ago [33-35, 37], there has been a great expansion in the number of protein tools used, circuits targeted, and behaviors analyzed. Continued improvement of optogenetic tools in terms of the sensitivity and temporal control of manipulations should lead to the development of novel and better behavioral assays to further aid in linking patterns of neural activity to their corresponding behaviors [37]. Moreover, optogenetic approaches may help predict how changes in circuit function alter cognition and behavior, elucidating how circuit-level manipulations may ultimately be used for the treatment of neurobehavioral disorders [38].
The utilization of diverse and novel models, such as the zebrafish, may foster a better understanding of the complex actions of cognitive enhancing or neuroprotective agents, eventually leading to more effective treatments for various cognitive and affective brain disorders. The sensitivity of some zebrafish memory-related behaviors to nootropic compounds further supports their utility in developing novel screens for compounds with potential cognitive enhancer properties. Additionally, the use of various mutant or transgenic zebrafish may enable further characterization of genetic and physiological mechanisms involved in learning and memory, as well as in fish sensitivity to cognitive enhancing or neuroprotective drugs.
Continued advances in optogenetics, high-resolution in vivo imaging, and bioinformatics techniques have created new opportunities to obtain a greater understanding of higher brain functions under healthy and diseased conditions. Recent studies have highlighted the potential of zebrafish for detailed measurements of neuronal activity patterns, manipulations of defined cell types in vivo, and for studies of causal relationships between circuit function and behavior. The small brain of zebrafish may also be exploited in future research for the reconstruction of neuronal wiring diagrams by 3D electron microscopy [165]. The exhaustive and quantitative analysis of neuronal activity and connectivity will eventually be important to derive principles governing neuronal circuit function by at both the theoretical and practical levels, especially in relation to disease pathogenesis. In light of their relatively complex cognition and elaborate behavioral repertoire, such circuit analyses is not limited to simple systems and should be applied to neural pathways underlying higher order processing relevant to cognitive deficits [166].
ACKNOWLEDGEMENTS
The study was supported by the NIH/NIDA R03 DA030900-01, Tulane University SOM’s ‘Synergy’ grant, as well as Newcomb Fellows and CELT grants to AVK. The authors would like to thank A. Roth, S. Gaikwad, J. Cachat and E. Kyzar for their help with this study. The authors have no conflict of interest.
CONFLICT OF INTEREST
The authors confirm that this article content has no conflicts of interest.
1. Foley JA, Kaschel R, Logie RH, Della S S. Dual-task performance in Alzheimer's disease, mild cognitive impairment, and normal ageing. Arch. Clin. Neuropsychol. 2011;26(4):340–8. [PubMed]
2. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol . 2000;14(1):1–21. [PubMed]
3. Sasson N, Tsuchiya N, Hurley R, Couture SM, Penn DL, Adolphs R, Piven J. Orienting to social stimuli differentiates social cognitive impairment in autism and schizophrenia. Neuropsychologia. 2007;45(11):2580–8. [PMC free article] [PubMed]
4. Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain. 1997;120( Pt 12):2207–17. [PubMed]
5. David BA, Ascher DB, Crespi GAN, Ng HL, Morton CJ, Parker MW, Miles LA. OMICS Publishing Group; 2008. Novel Therapeutic Approaches to Treat Alzheimer’s Disease and Memory Disorders.
6. Malhi GS, Loo C, Cahill CM, Lagopoulos J, Mitchell P, Sachdev P. "Getting physical": the management of neuropsychiatric disorders using novel physical treatments. Neuropsychiatr. Dis. Treat. 2006;2(2):165–79. [PMC free article] [PubMed]
7. Best JD, Alderton WK. Zebrafish: An in vivo model for the study of neurological diseases. Neuropsychiatr. Dis. Treat. 2008;4(3):567–76. [PMC free article] [PubMed]
8. Cerutti DT, Levin ED. In: Cognitive Impairment Models Using Complementary Species, in Animal Models of Cognitive Impairment. Levin ED, Buccafusco JJ, editors. Boca Raton (FL); 2006. [PubMed]
9. Bruce-Keller AJ, Gupta S, Knight AG, Beckett TL, McMullen J M, Davis PR, Murphy MP, Van ELJ, St Clair D, Keller JN. Cognitive impairment in humanized APPxPS1 mice is linked to Abeta(1-42) and NOX activation. Neurobiol. Dis. 2011;44(3):317–26. [PMC free article] [PubMed]
10. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, Garner CC. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 2007;10(4):411–3. [PubMed]
11. Chin J, Palop JJ, Puoliväli J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2005;25(42):9694–703. [PubMed]
12. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991;30(4):572–80. [PubMed]
13. Kalueff AV, Wheaton M, Murphy DL. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav Brain Res . 2007;179(1):1–18. [PubMed]
14. Rodriguiz RM, Wetsel WC. In: Assessments of Cognitive Deficits in Mutant Mice, in Animal Models of Cognitive Impairment. Levin ED, Buccafusco JJ, editors. Boca Raton (FL); 2006. [PubMed]
15. Bussey TJ, Holmes A, Lyon L, Mar AC, McAllister KA, Nithianantharajah J, Oomen CA, Saksida LM. New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology. 2012;62(3):1191–203. [PMC free article] [PubMed]
16. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 2006;184(3-4):523–39. [PubMed]
17. Mathur P, Guo S. Use of zebrafish as a model to understand mechanisms of addiction and complex neurobehavioral phenotypes. Neurobiol. Dis. 2010;40(1):66–72. [PMC free article] [PubMed]
18. Sison M, Gerlai R. Associative learning in zebrafish (Danio rerio) in the plus maze. Behav Brain Res. 2010;207(1):99–104. [PMC free article] [PubMed]
19. Best JD, Berghmans S, Hunt JJ, Clarke SC, Fleming A, Goldsmith P, Roach AG. Non-associative learning in larval zebrafish. Neuropsychopharmacology. 2008;33(5):1206–15. [PubMed]
20. Al-Imari L, Gerlai R. Sight of conspecifics as reward in associative learning in zebrafish (Danio rerio) Behav. Brain Res. 2008;189(1):216–9. [PubMed]
21. Wong K, Elegante M, Bartels B, Elkhayat S, Tien D, Roy S, Goodspeed J, Suciu C, Tan J, Grimes C, Chung A, Rosenberg M, Gaikwad S, Denmark A, Jackson A, Kadri F, Chung KM, Stewart A, Gilder T, Beeson E, Zapolsky I, Wu N, Cachat J, Kalueff AV. Analyzing habituation responses to novelty in zebrafish (Danio rerio) Behav. Brain Res. 2010;208(2):450–7. [PubMed]
22. Raymond J, Chanin S, Stewart AM, Kyzar E, Gaikwad S, Roth A, Bruce I, Fryar C, Varga D, Enriquez J, Bagawandoss S, Pham M, Zapolsky I, Green J, Desmond D, Hester J, Kalueff AV, Kalueff AV, Stewart AM. In: Assessing habituation phenotypes in adult zebrafish: intra- and inter-trial habituation to novelty, in Zebrafish Protocols for Neurobehavioral Research. AV Kalueff, AM Stewart., editors. New York: Humana Press; 2012.
23. Angelucci ME, Vital MA, Cesário C, Zadusky CR, Rosalen PL, Da Cunha C. The effect of caffeine in animal models of learning and memory. Eur. J. Pharmacol. 1999;373(2-3):135–40. [PubMed]
24. Maroun M, Akirav I. Arousal and stress effects on consolidation and reconsolidation of recognition memory. Neuropsychopharmacology. 2008;33(2):394–405. [PubMed]
25. Mello PB, Benetti F, Cammarota M, Izquierdo I. Effects of acute and chronic physical exercise and stress on different types of memory in rats. An Acad Bras Cienc. 2008;80(2):301–9. [PubMed]
26. Best JD, Berghmans S, Hunt JJFG, Fleming A, Goldsmith P, Roach AG. Non-associative learning in larval zebrafish is mediated by the nicotinic and NMDA pathways. in British Pharmacological Society. Brighton, UK: 2007.
27. Williams FE, White D, Messer WS. A simple spatial alternation task for assessing memory function in zebrafish. Behav. Processes. 2002;58(3):125–132. [PubMed]
28. Yu L, Tucci V, Kishi S, Zhdanova IV. Cognitive aging in zebrafish. PLoS One. 2006;1:e14. [PMC free article] [PubMed]
29. Kishi S, Slack BE, Uchiyama J, Zhdanova IV. Zebrafish as a genetic model in biological and behavioral gerontology: where development meets aging in vertebrates--a mini-review. Gerontology. 2009;55(4):430–41. [PMC free article] [PubMed]
30. Postlethwait JH, Woods IG, Ngo-Hazelett P, Yan YL, Kelly PD, Chu F, Huang H, Hill-Force A, Talbot WS. Zebrafish comparative genomics and the origins of vertebrate chromosomes. Genome Res. 2000;10(12):1890–902. [PubMed]
31. Levin ED. Zebrafish assessment of cognitive improvement and anxiolysis: filling the gap between in vitro and rodent models for drug development. Rev. Neurosci. 2011;22(1):75–84. [PubMed]
32. Del Bene F, Wyart C. Optogenetics: A new enlightenment age for zebrafish neurobiology. Dev. Neurobiol. 2012;72(3):404–14. [PubMed]
33. Higashijima S, Masino MA, Mandel G, Fetcho JR. Imaging neuronal activity during zebrafish behavior with a genetically encoded calcium indicator. J. Neurophysiol. 2003;90(6):3986–97. [PubMed]
34. Tsuruwaka Y, Konishi T, Miyawaki A, Takagi M. Real-time monitoring of dynamic intracellular Ca(2+) movement during early embryogenesis through expression of yellow cameleon. Zebrafish. 2007;4(4):253–60. [PubMed]
35. Dreosti E, Odermatt B, Dorostkar MM, Lagnado L. A genetically encoded reporter of synaptic activity in vivo. Nat. Methods. 2009;6(12):883–9. [PMC free article] [PubMed]
36. Knopfel T, Diez-Garcia J, Akemann W. Optical probing of neuronal circuit dynamics: genetically encoded versus classical fluorescent sensors. Trends Neurosci. 2006;29(3):160–6. [PubMed]
37. Simmich J, Staykov E, Scott E. Zebrafish as an appealing model for optogenetic studies. Prog. Brain Res. 2012;196:145–62. [PubMed]
38. Peca J, Feng G. Neuroscience: When lights take the circuits out. Nature. 2011;477(7363):165–6. [PubMed]
39. Levin ED, Chen E. Nicotinic involvement in memory function in zebrafish. Neurotoxicol. Teratol. 2004;26(6):731–5. [PubMed]
40. Mathur P, Lau B, Guo S. Conditioned place preference behavior in zebrafish. Nat. Protoc. 2011;6(3):338–45. [PubMed]
41. Grossman L, Stewart A, Gaikwad S, Utterback E, Wu N, Dileo J, Frank K, Hart P, Howard H, Kalueff AV. Effects of piracetam on behavior and memory in adult zebrafish. Brain Res. Bull. 2011. [PubMed]
42. Platt D, Horn J, Summa JD, Schmitt-Rüth R, Kauntz J, Krönert E. On the efficacy of piracetam in geriatric patients with acute cerebral ischemia: a clinically controlled double-blind study. Arch. Gerontol. Geriatr. 1993;16(2):149–64. [PubMed]
43. Winnicka K, Tomasiak M, Bielawska A. Piracetam--an old drug with novel properties? Acta Pol. Pharm. 2005;62(5):405–9. [PubMed]
44. Bhattacharya SK, Sen AP, Upadhyay SN, Jaiswal AK. Anxiolytic activity of piracetam, a nootropic agent, following subchronic administration in rodents. Indian J. Exp. Biol. 1993;31(11):902–7. [PubMed]
45. Bhattacharya SK, Upadhyay SN, Jaiswal AK, Sen AP. Latency of memory consolidation induced in mice by piracetam, a nootropic agent. Indian J. Exp. Biol. 1993;31(11):898–901. [PubMed]
46. Gaikwad S, Stewart A, Hart P, Wong K, Piet V, Cachat J, Kalueff AV. Acute stress disrupts performance of zebrafish in the cued and spatial memory tests: the utility of fish models to study stress-memory interplay. Behav. Proc. 2011;87(2):224–30. [PubMed]
47. Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuro-enhancement in healthy individuals: A systematic review. Pharmacol. Res. 2010;62(3):187–206. [PubMed]
48. Wesensten NJ. Effects of modafinil on cognitive performance and alertness during sleep deprivation. Curr. Pharm. Des. 2006;12(20):2457–71. [PubMed]
49. Sigurgeirsson B, Thornorsteinsson H, Arnardóttir H, Jóhannesdóttir IT, Karlsson KA. Effects of modafinil on sleep-wake cycles in larval zebrafish. Zebrafish. 2011;8(3):133–40. [PubMed]
50. Firstova I, Dolotov OV, Kondrakhin A, Dubynina EV, Grivennikov IA, Kovalev GI. Effects of nootropic drugs on hippocampal and cortical BDNF levels in mice with different exploratory behavior efficacy] Eksp. Klin. Farmakol. 2009;72(6):3–6. [PubMed]
51. Sansone M, Castellano C, Battaglia M, Ammassari-Teule M. Effects of oxiracetam-nicotine combinations on active and passive avoidance learning in mice. Pharmacol. Biochem. Behav. 1991;39(1):197–200. [PubMed]
52. Zhao X, Kuryatov A, Lindstrom JM, Yeh JZ, Narahashi T. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Mol. Pharmacol. 2001;59(4):674–83. [PubMed]
53. Eilam D, Golani I. Home base behavior of rats (Rattus norvegicus) exploring a novel environment. Behav. Brain Res. 1989;34(3):199–211. [PubMed]
54. Golani I, Benjamini Y, Eilam D. Stopping behavior: constraints on exploration in rats (Rattus norvegicus) Behav. Brain Res. 1993;53(1-2):21–33. [PubMed]
55. Tchernichovski O, Benjamini Y, Golani I. Constraints and the emergence of 'free' exploratory behavior in rat ontogeny. Behaviour. 1996;133(7/8):519–539.
56. Stewart A, Cachat J, Wong K, Wu N, Grossman L, Suciu C, Goodspeed J, Elegante M, Bartels B, Elkhayat S, Tien D, Gaikwad S, Kadri F, Chung KM, Tan J, Denmark A, Gilder T, DiLeo J, Chang K, Utterback E, Viviano P, Kalueff AV, Kalueff AV, Cachat J. In: Phenotyping of zebrafish homebase behaviors in novelty-based tests, in Zebrafish Neurobehavioral Protocols. AV Kalueff, J Cachat., editors. New York: Humana Press; 2010.
57. Stewart A, Cachat J, Wong K, Gaikwad S, Gilder T, DiLeo J, Chang K, Utterback E, Kalueff AV. Homebase behavior of zebrafish in novelty-based paradigms. Behav. Process. 2010;85(2):198–203. [PubMed]
58. Rosemberg DB, Rico EP, Mussulini BH, Piato AL, Calcagnotto ME, Bonan CD, Dias RD, Blaser RE, Souza DO, de Oliveira DL. Differences in Spatio-Temporal Behavior of Zebrafish in the Open Tank Paradigm after a Short-Period Confinement into Dark and Bright Environments. PLoS One. 2011;6(5):e19397. [PMC free article] [PubMed]
59. Kalueff AV, Kyzar E, Cachat J, Gaikwad S, Green J, Roth A , Collins C, El-Ounsi M, Pham M, Davis A, Landsman S . Novel experimental models of hallucinogenic drug action, anxiety and depression - from fish to humans. in 17th Stress and Behavior ISBS Conference; St. Petersburg, Russia. 2012.
60. Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J. Ethnopharmacol. 2008;115(1):9–24. [PubMed]
61. Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J. Forensic Sci. 2012;57(2):398–412. [PubMed]
62. Schechter MD, Gordon TL. Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity. Eur. J. Pharmacol. 1993;249(1):79–84. [PubMed]
63. Stewart AM, Gaikwad S, Kyzar E, Kalueff AV. Understanding spatio-temporal strategies of adult zebrafish exploration in the open field test. Brain Res. 2012;1451:44–52. [PubMed]
64. Gerhard GS. Comparative aspects of zebrafish (Danio rerio) as a model for aging research. Exp. Gerontol. 2003;38(11-12):1333–41. [PubMed]
65. Zhdanova IV, Yu L, Lopez-Patino M, Shang E, Kishi S, Guelin E. Aging of the circadian system in zebrafish and the effects of melatonin on sleep and cognitive performance. Brain Res. Bull. 2008;75(2-4):433–41. [PMC free article] [PubMed]
66. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron . 2000;28(2):325–34. [PubMed]
67. Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology. 2000;23(3):223–39. [PubMed]
68. Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron. 2006;52(1):179–96. [PubMed]
69. Powell SB, Zhou X, Geyer MA. Prepulse inhibition and genetic mouse models of schizophrenia. Behav. Brain Res. 2009;204(2): 282–94. [PMC free article] [PubMed]
70. Burgess HA, Granato M. Sensorimotor gating in larval zebrafish. J .Neurosci. 2007;27(18):4984–94. [PubMed]
71. Tek C, Gold J, Blaxton T, Wilk C, McMahon RP, Buchanan RW. Visual perceptual and working memory impairments in schizophrenia. Arch. Gen. Psychiatry. 2002;59(2):146–53. [PubMed]
72. Manns JR, Stark CE, Squire LR. The visual paired-comparison task as a measure of declarative memory. Proc. Natl. Acad. Sci. U. S .A. 2000;97(22):12375–9. [PubMed]
73. Powell KJ, Hori SE, Leslie R, Andrieux A, Schellinck H, Thorne M, Robertson GS. Cognitive impairments in the STOP null mouse model of schizophrenia. Behav. Neurosci. 2007;121(5):826–35. [PubMed]
74. Kvajo M, McKellar H, Arguello PA, Drew LJ, Moore H, MacDermott AB, Karayiorgou M, Gogos JA. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl. Acad. Sci. 2008;105(19):7076–7081. [PubMed]
75. Redrobe JP, Bull S, Plath N. Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia. Front. Psychiatry. 2010;1:146. [PMC free article] [PubMed]
76. Ogwang SP. Inspection of a novel object by wild and laboratory Zebrafish (Danio rerio H) in the presence and absence of alarm substance. in Department of Biology University of Bergen: Bergen. 2008. p. 68.
77. Egan RJ, Bergner CL, Hart PC, Cachat JM, Canavello PR, Elegante MF, Elkhayat SI, Bartels BK, Tien A K, Tien DH, Mohnot S, Beeson E, Glasgow E, Amri H, Zukowska Z, Kalueff AV. Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. Behav. Brain Res. 2009;205(1):38–44. [PMC free article] [PubMed]
78. Wong K, Elegante M, Bartels B, Elkhayat S, Tien D, Roy S, Goodspeed J, Suciu C, Tan J, Grimes C, Chung A, Rosenberg M, Gaikwad S, Denmark A, Jackson A, Kadri F, Chung km, Stewart A, Gilder T, Beeson E, Zapolsky I, Wu N, Cachat J, Kalueff AV. Analyzing habituation responses to novelty in zebrafish (Danio rerio) Behav. Brain Res . 2009. [PubMed]
79. Rihel J, Schier AF. Behavioral screening for neuroactive drugs in zebrafish. Dev. Neurobiol. 2012;72:373–85. [PubMed]
80. Cachat J, Canavello P, Elegante M, Bartels B, Hart P, Bergner C, Egan R, Duncan A, Tien D, Chung A, Wong K, Goodspeed J, Tan J, Grimes C, Elkhayat S, Suciu C, Rosenberg M, Chung KM, Kadri F, Roy S, Gaikwad S, Stewart A, Zapolsky I, Gilder T, Mohnot S, Beeson E, Amri H, Zukowska Z, Soignier RD, Kalueff AV. Modeling withdrawal syndrome in zebrafish. Behav. Brain Res. 2010;208(2):371–6. [PubMed]
81. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408–14. [PubMed]
82. Gallagher M, Colombo PJ. Ageing: the cholinergic hypothesis of cognitive decline. Curr. Opin, Neurobiol. 1995;5(2):161–8. [PubMed]
83. Lawrence AD, Sahakian BJ. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem. Res. 1998;23(5):787–94. [PubMed]
84. Sirvio J. Strategies that support declining cholinergic neuro-transmission in Alzheimer's disease patients. Gerontology. 1999;45 Suppl 1:3–14. [PubMed]
85. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch. Intern. Med. 1998;158(9):1021–31. [PubMed]
86. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs. 2001;61(1):41–52. [PubMed]
87. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH. Donepezil therapy in clinical practice: a randomized crossover study. Arch. Neurol. 2000;57(1):94–9. [PubMed]
88. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs. 2001;15(5):375–90. [PubMed]
89. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57(3):481–8. [PubMed]
90. Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F. Cognitive Enhancing Properties and Tolerability of Cholinergic Agents in Mice: A Comparative Study of Nicotine, Donepezil, and SIB-1553A, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors. Neuropsychopharmacology. 2003;28(7):1235–1246. [PubMed]
91. Levin ED, Rose JE, Abood L. Effects of nicotinic dimethylaminoethyl esters on working memory performance of rats in the radial-arm maze. Pharmacol. Biochem. Behav. 1995;51(2-3):369–73. [PubMed]
92. Spinelli S, Ballard T, Feldon J, Higgins GA, Pryce CR. Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys. Neuropharmacology . 2006;51(2):238–50. [PubMed]
93. Hoyle E, Genn RF, Fernandes C, Stolerman IP. Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task. Psychopharmacology (Berl) 2006;189(2):211–23. [PMC free article] [PubMed]
94. Katner SN, Davis SA, Kirsten AJ, Taffe MA. Effects of nicotine and mecamylamine on cognition in rhesus monkeys. Psychopharmacology (Berl) 2004;175(2):225–40. [PMC free article] [PubMed]
95. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry. 1995;38(1): 22–33. [PubMed]
96. Riley BP, Makoff A, Mogudi-Carter M, Jenkins T, Williamson R, Collier D, Murray R. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am. J. Med. Genet. 2000;96(2):196–201. [PubMed]
97. Ackerman KM, Nakkula R, Zirger JM, Beattie CE, Boyd RT. Cloning and spatiotemporal expression of zebrafish neuronal nicotinic acetylcholine receptor alpha 6 and alpha 4 subunit RNAs. Dev. Dyn. 2009;238(4):980–92. [PubMed]
98. Zirger JM, Beattie CE, McKay DB, Boyd RT. Cloning and expression of zebrafish neuronal nicotinic acetylcholine receptors. Gene Expr. Patterns. 2003;3(6):747–54. [PubMed]
99. Klee EW, Ebbert JO, Schneider H, Hurt RD, Ekker SC. Zebrafish for the study of the biological effects of nicotine. Nicotine Tob Res. 2011;13(5):301–12. [PMC free article] [PubMed]
100. Klee EW, Schneider H, Clark KJ, Cousin MA, Ebbert JO, Hooten WM, Karpyak VM, Warner DO, Ekker SC. Zebrafish: a model for the study of addiction genetics. Hum. Genet. 2012;131(6):977–1008. [PubMed]
101. Aley KO, Levine JD. Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat. J. Neurosci. 1997;17(20):8018–23. [PubMed]
102. Levin ED, Limpuangthip J, Rachakonda T, Peterson M. Timing of nicotine effects on learning in zebrafish. Psychopharmacology (Berl) 2006;184(3-4):547–52. [PubMed]
103. Leiser SC, Bowlby MR, Comery TA, Dunlop J. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol. Ther. 2009;122(3):302–11. [PubMed]
104. Bencan Z, Levin ED. The role of alpha7 and alpha4beta2 nicotinic receptors in the nicotine-induced anxiolytic effect in zebrafish. Physiol Behav. 2008;95(3):408–12. [PMC free article] [PubMed]
105. Alkondon M, Pereira EF, Albuquerque EX. alpha-bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices. Brain Res. 1998;810(1-2):257–63. [PubMed]
106. Frazier CJ, Buhler AV, Weiner JL, Dunwiddie TV. Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J. Neurosci. 1998;18(20):8228–35. [PubMed]
107. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature. 1996;383(6602):713–6. [PubMed]
108. Kumari V, Checkley SA, Gray JA. Effect of cigarette smoking on prepulse inhibition of the acoustic startle reflex in healthy male smokers. Psychopharmacology (Berl) 1996;128(1):54–60. [PubMed]
109. Duncan E, Madonick S, Chakravorty S, Parwani A, Szilagyi S, Efferen T, Gonzenbach S, Angrist B, Rotrosen J. Effects of smoking on acoustic startle and prepulse inhibition in humans. Psychopharmacology (Berl): 2001;156(2-3):266–72. [PubMed]
110. Hutchison KE, Niaura R, Swift R. The effects of smoking high nicotine cigarettes on prepulse inhibition, startle latency, and subjective responses. Psychopharmacology (Berl) 2000;150(3):244–52. [PubMed]
111. Acri JB. Nicotine modulates effects of stress on acoustic startle reflexes in rats: dependence on dose, stressor and initial reactivity. Psychopharmacology (Berl) 1994;116(3):255–65. [PubMed]
112. Curzon P, Kim DJ, Decker MW. Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. Pharmacol. Biochem. Behav. 1994;49(4):877–82. [PubMed]
113. Faraday MM, O'Donoghue VA, Grunberg NE. Effects of nicotine and stress on startle amplitude and sensory gating depend on rat strain and sex. Pharmacol. Biochem. Behav. 1999;62(2):273–84. [PubMed]
114. Mackeprang T, Kristiansen KT, Glenthoj BY. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol. Psychiatry. 2002;52(9):863–73. [PubMed]
115. Kumari V, Soni W, Mathew VM, Sharma T. Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication. Arch. Gen. Psychiatry. 2000;57(6):609–14. [PubMed]
116. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001;156(2-3):234–58. [PubMed]
117. Gogos A, Bogeski M, van den Buuse M. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology. Behav. Pharmacol. 2008;19(5-6):548–61. [PubMed]
118. Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 1998;24(2):285–301. [PubMed]
119. Johansson C, Jackson DM, Zhang J, Svensson L. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats. Pharmacol. Biochem. Behav. 1995;52(4):649–54. [PubMed]
120. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry . 2000;157(4):514–20. [PubMed]
121. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br. J. Psychiatry. 2010;196(6):434–9. [PMC free article] [PubMed]
122. Jones DNC, Gartlon JE, Minassian A, Perry W, Geyer M. Developing new drugs for schizophrenia: from animals to the clinic, in Animal and translational models for CNS drug discovery. In: McArthur R, Borsini F, editors. London: Academic Press; 2008. pp. 199–261.
123. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 2011;11(1):59–67. [PubMed]
124. Seibt KJ, Piato AL, da Luz Oliveira R, Capiotti KM, Vianna MR, Bonan CD. Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio) Behav. Brain Res. 2011;224(1):135–9. [PubMed]
125. Sison M, Gerlai R. Behavioral performance altering effects of MK-801 in zebrafish (Danio rerio) Behav. Brain Res. 2011;220(2):331–7. [PMC free article] [PubMed]
126. Swain HA, Sigstad C, and Scalzo FM. Effects of dizocilpine (MK-801) on circling behavior, swimming activity, and place preference in zebrafish (Danio rerio) Neurotoxicol. Teratol. 2004;26(6):725–9. [PubMed]
127. Stewart A, Gaikwad S, Kyzar E, Green J, Roth A, Kalueff AV. Modeling anxiety using adult zebrafish: a conceptual review. Neuropharmacology. 2012;62(1):135–43. [PMC free article] [PubMed]
128. Sison M, Gerlai R. Associative learning performance is impaired in zebrafish (Danio rerio) by the NMDA-R antagonist MK-801. Neurobiol. Learn. Mem. 2011;96(2):230–7. [PMC free article] [PubMed]
129. Kim YH, Lee Y, Kim D, Jung MW, Lee CJ. Scopolamine-induced learning impairment reversed by physostigmine in zebrafish. Neurosci. Res. 2010;67(2):156–61. [PubMed]
130. Riehl R, Kyzar E, Allain A, Green J, Hook M, Monnig L, Rhymes K, Roth A, Pham M, Razavi R, Dileo J, Gaikwad S, Hart P, Kalueff AV. Behavioral and physiological effects of acute ketamine exposure in adult zebrafish. Neurotoxicol. Teratol. 2011;33(6):658–667. [PubMed]
131. Carvan MJ, 3rd, Loucks E, Weber DN, Williams FE. Ethanol effects on the developing zebrafish: neurobehavior and skeletal morphogenesis. Neurotoxicol. Teratol. 2004;26(6):757–68. [PubMed]
132. Gerlai R. High-throughput behavioral screens: the first step towards finding genes involved in vertebrate brain function using zebrafish. Molecules. 2010;15(4):2609–22. [PubMed]
133. Tomasiewicz HG, Flaherty DB, Soria JP, Wood JG. Transgenic zebrafish model of neurodegeneration. J. Neurosci. Res. 2002;70(6):734–45. [PubMed]
134. Newman M, Musgrave IF, Lardelli M. Alzheimer disease: amyloidogenesis, the presenilins and animal models. Biochim. Biophys. Acta . 2007;1772(3):285–97. [PubMed]
135. Bird TD. Genetic factors in Alzheimer's disease. N. Engl. J. Med. 2005;352(9):862–4. [PubMed]
136. Chen Q, Nakajima A, Choi SH, Xiong X, Tang YP. Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse. J. Neurosci. Res. 2008;86(7):1615–25. [PubMed]
137. Newman M, Verdile G, Martins RN, Lardelli M. Zebrafish as a tool in Alzheimer's disease research. Biochim. Biophys. Acta. 2011;1812(3):346–52. [PubMed]
138. Wood JD, Bonath F, Kumar S, Ross CA, Cunliffe VT. Disrupted-in-schizophrenia 1 and neuregulin 1 are required for the specification of oligodendrocytes and neurones in the zebrafish brain. Hum. Mol. Genet. 2009;18(3):391–404. [PubMed]
139. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, Wu D, Xue R, Andradé M, Tankou S, Mori S, Gallagher M, Ishizuka K, Pletnikov M, Kida S, Sawa A. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl. Acad Sci U S A . 2007;104(36):14501–6. [PubMed]
140. Li W, Zhou Y, Jentsch JD, Brown RA, Tian X, Ehninger D, Hennah W, Peltonen L, Lönnqvist J, Huttunen MO, Kaprio J, Trachtenberg JT, Silva AJ, Cannon TD. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl. Acad. Sci. U. S. A. 2007;104(46):18280–5. [PubMed]
141. Levin ED, Sledge D, Roach S, Petro A, Donerly S, Linney E. Persistent behavioral impairment caused by embryonic methylphenidate exposure in zebrafish. Neurotoxicol. Teratol. 2011;33(6):668–73. [PMC free article] [PubMed]
142. Lange M, Norton W, Coolen M, Chaminade M, Merker S, Proft F, Schmitt A, Vernier P, Lesch KP, Bally-Cuif L. The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development. Mol. Psychiatry. 2012;17(9):946–54. [PubMed]
143. Ullmann JF, Cowin G, Kurniawan ND, Collin SP. A three-dimensional digital atlas of the zebrafish brain. Neuroimage. 2010;51(1):76–82. [PubMed]
144. Hua X, Leow AD, Lee S, Klunder AD, Toga AW, Lepore N, Chou YY, Brun C, Chiang MC, Barysheva M, Jack CR, Jr, Bernstein MA, Britson PJ, Ward CP, Whitwell JL, Borowski B, Fleisher AS, Fox NC, Boyes RG, Barnes J, Harvey D, Kornak J, Schuff N, Boreta L, Alexander GE, Weiner MW, Thompson PM. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage. 2008;41(1):19–34. [PMC free article] [PubMed]
145. Rusinek H, De Santi S, Frid D, Tsui WH, Tarshish CY, Convit A, de Leon MJ. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology. 2003;229(3):691–6. [PubMed]
146. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry. 2007;78(3):254–9. [PMC free article] [PubMed]
147. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, Dalrymple-Alford JC, Anderson TJ. Grey matter atrophy in cognitively impaired Parkinson's disease. J. Neurol. Neurosurg. Psychiatry . 2012;83(2):188–94. [PubMed]
148. Sporns O, Tononi G, Kotter R. The human connectome: A structural description of the human brain. PLoS Comput. Biol. 2005;1(4):e42. [PMC free article] [PubMed]
149. Potikanond D, Verbeek F. Amsterdam, Netherlands: 2011. 3D Visual Integration of Spatio- Temporal Gene Expression Patterns on Digital Atlas of Zebrafish Embryo using Web Service. in Int. Conf. on Advances in Communication and Information Technology.
150. Axer M, Amunts K, Grässel D, Palm C, Dammers J, Axer H, Pietrzyk U, Zilles K. A novel approach to the human connectome: ultra-high resolution mapping of fiber tracts in the brain. Neuroimage. 2011;54(2):1091–101. [PubMed]
151. Bullmore ET, Bassett DS. Brain Graphs: Graphical Models of the Human Brain Connectome. Annu. Rev. Clin. Psychol. 2011. [PubMed]
152. Sporns O. The human connectome: a complex network. Ann. N. Y. Acad. Sci. 2011;1224:109–25. [PubMed]
153. Weissman TA, Sanes JR, Lichtman JW, Livet J. Generation and imaging of Brainbow mice. Cold Spring Harb. Protoc. 2011. pp. 851–6. [PubMed]
154. Livet J. The brain in color: transgenic "Brainbow" mice for visualizing neuronal circuits. Med. Sci. (Paris) 2007;23(12):1173–6. [PubMed]
155. Hampel S, Chung P, McKellar CE, Hall D, Looger LL, Simpson JH. Drosophila Brainbow: a recombinase-based fluorescence labeling technique to subdivide neural expression patterns. Nat. Methods. 2011;8(3):253–9. [PMC free article] [PubMed]
156. Pan YA, Livet J, Sanes JR, Lichtman JW, Schier AF. Multicolor Brainbow imaging in zebrafish. Cold Spring Harb. Protoc. 2011. p. pdb prot5546. [PMC free article] [PubMed]
157. Boyden ES. A history of optogenetics: the development of tools for controlling brain circuits with light. F1000 Biol. Rep. 2011;3:11. [PMC free article] [PubMed]
158. Bernstein JG, Boyden ES. Optogenetic tools for analyzing the neural circuits of behavior. Trends Cogn. Sci. 2011;15(12):592–600. [PMC free article] [PubMed]
159. Mancuso JJ, Kim J, Lee S, Tsuda S, Chow NB, Augustine GJ. Optogenetic probing of functional brain circuitry. Exp. Physiol. 2011;96(1):26–33. [PubMed]
160. Zeng H, Madisen L. Mouse transgenic approaches in optogenetics. Prog. Brain Res. 2012;196:193–213. [PMC free article] [PubMed]
161. Han X. Optogenetics in the nonhuman primate. Prog. Brain Res. 2012;196:215–33. [PMC free article] [PubMed]
162. Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O'Shea DJ, Sohal VS, Goshen I, Finkelstein J, Paz JT, Stehfest K, Fudim R, Ramakrishnan C, Huguenard JR, Hegemann P, Deisseroth K. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature. 2011;477(7363):171–8. [PubMed]
163. Kimura Y, Okamura Y, Higashijima S. alx, a zebrafish homolog of Chx10, marks ipsilateral descending excitatory interneurons that participate in the regulation of spinal locomotor circuits. J. Neurosci. 2006;26(21):5684–97. [PubMed]
164. Yaksi E, Judkewitz B, Friedrich R. Topological reorganization of odor representations in the olfactory bulb. PLoS Biol. 2007;5(7):e178. [PMC free article] [PubMed]
165. Helmstaedter M, Briggman KL, Denk W. 3D structural imaging of the brain with photons and electrons. Curr. Opin. Neurobiol. 2008;18(6):633–41. [PubMed]
166. Friedrich RW, Jacobson GA, Zhu P. Circuit Neuroscience in Zebrafish. Curr. Biol. 2010;20(8):R371–R381. [PubMed]
Articles from Current Neuropharmacology are provided here courtesy of
Bentham Science Publishers